Loading…

Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach

Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacognosy Magazine 2021-04, Vol.17 (74), p.268-274
Main Authors: Yun, Debo, Yang, Yujiao, Shang, Bin, Dong, Heng, Luo, Bo, Alahmadi, Tahani, Luo, Qing
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3
container_end_page 274
container_issue 74
container_start_page 268
container_title Pharmacognosy Magazine
container_volume 17
creator Yun, Debo
Yang, Yujiao
Shang, Bin
Dong, Heng
Luo, Bo
Alahmadi, Tahani
Luo, Qing
description Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.
doi_str_mv 10.4103/pm.pm_261_20
format article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2553415866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669072185</galeid><sourcerecordid>A669072185</sourcerecordid><originalsourceid>FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</originalsourceid><addsrcrecordid>eNptkW9r2zAQxs1YYV27d_sAgr2dE0mWZWUvBqF0ayFspbSvxVk-J2psyZPshnyPfeApyf4wKAKdOH7P6e6eLHvP6EwwWsyHfjb0mkumOX2VndNFJXNBJX99fBc54wv5Jnsb4xOlpWK0Os9-LscR3QSj9Y74lmxtQOc7Yl3bQd8f89Y1k8GG1Htio9lgb8084IChneJBZjBgHeAogmCOpeIY_BbJswXysLoXc_JtdX9XkGjXDjrr1mSAcbOD_SeydEmXwGdPYBiCB7O5zM5a6CK--x0vsscv1w9XN_nq-9fbq-UqN7ziY17xsuEVggRVgKoEU0grUTay5G2NpjEoTVUw1QiaLiZqIbkBUGUtF6qp2-Ii-3Cqm779MWEc9ZOfQmowal6WhWClkvIftYYOdZrRjwFMn1ahl1IuaMWZKhM1e4FKpznsyztsbcr_J_h4EpjgYwzY6iHYHsJeM6oPdurk5V87E_75hO98N2KI227aYdA9Nlvndy9qUlD6j7_FL39iqs4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2553415866</pqid></control><display><type>article</type><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><source>Publicly Available Content Database</source><source>Alma/SFX Local Collection</source><creator>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</creator><creatorcontrib>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</creatorcontrib><description>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</description><identifier>ISSN: 0973-1296</identifier><identifier>EISSN: 0976-4062</identifier><identifier>DOI: 10.4103/pm.pm_261_20</identifier><language>eng</language><publisher>London: Wolters Kluwer India Pvt. Ltd</publisher><subject>Brain ; Inflammation ; Injuries ; Neurons ; Tumor necrosis factor-TNF</subject><ispartof>Pharmacognosy Magazine, 2021-04, Vol.17 (74), p.268-274</ispartof><rights>COPYRIGHT 2021 Medknow Publications and Media Pvt. Ltd.</rights><rights>2021. This article is published under (http://creativecommons.org/licenses/by-nc-sa/3.0/) (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2553415866?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590</link.rule.ids></links><search><creatorcontrib>Yun, Debo</creatorcontrib><creatorcontrib>Yang, Yujiao</creatorcontrib><creatorcontrib>Shang, Bin</creatorcontrib><creatorcontrib>Dong, Heng</creatorcontrib><creatorcontrib>Luo, Bo</creatorcontrib><creatorcontrib>Alahmadi, Tahani</creatorcontrib><creatorcontrib>Luo, Qing</creatorcontrib><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><title>Pharmacognosy Magazine</title><description>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</description><subject>Brain</subject><subject>Inflammation</subject><subject>Injuries</subject><subject>Neurons</subject><subject>Tumor necrosis factor-TNF</subject><issn>0973-1296</issn><issn>0976-4062</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkW9r2zAQxs1YYV27d_sAgr2dE0mWZWUvBqF0ayFspbSvxVk-J2psyZPshnyPfeApyf4wKAKdOH7P6e6eLHvP6EwwWsyHfjb0mkumOX2VndNFJXNBJX99fBc54wv5Jnsb4xOlpWK0Os9-LscR3QSj9Y74lmxtQOc7Yl3bQd8f89Y1k8GG1Htio9lgb8084IChneJBZjBgHeAogmCOpeIY_BbJswXysLoXc_JtdX9XkGjXDjrr1mSAcbOD_SeydEmXwGdPYBiCB7O5zM5a6CK--x0vsscv1w9XN_nq-9fbq-UqN7ziY17xsuEVggRVgKoEU0grUTay5G2NpjEoTVUw1QiaLiZqIbkBUGUtF6qp2-Ii-3Cqm779MWEc9ZOfQmowal6WhWClkvIftYYOdZrRjwFMn1ahl1IuaMWZKhM1e4FKpznsyztsbcr_J_h4EpjgYwzY6iHYHsJeM6oPdurk5V87E_75hO98N2KI227aYdA9Nlvndy9qUlD6j7_FL39iqs4</recordid><startdate>20210401</startdate><enddate>20210401</enddate><creator>Yun, Debo</creator><creator>Yang, Yujiao</creator><creator>Shang, Bin</creator><creator>Dong, Heng</creator><creator>Luo, Bo</creator><creator>Alahmadi, Tahani</creator><creator>Luo, Qing</creator><general>Wolters Kluwer India Pvt. Ltd</general><general>Medknow Publications and Media Pvt. Ltd</general><general>Sage Publications Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20210401</creationdate><title>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</title><author>Yun, Debo ; Yang, Yujiao ; Shang, Bin ; Dong, Heng ; Luo, Bo ; Alahmadi, Tahani ; Luo, Qing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Brain</topic><topic>Inflammation</topic><topic>Injuries</topic><topic>Neurons</topic><topic>Tumor necrosis factor-TNF</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yun, Debo</creatorcontrib><creatorcontrib>Yang, Yujiao</creatorcontrib><creatorcontrib>Shang, Bin</creatorcontrib><creatorcontrib>Dong, Heng</creatorcontrib><creatorcontrib>Luo, Bo</creatorcontrib><creatorcontrib>Alahmadi, Tahani</creatorcontrib><creatorcontrib>Luo, Qing</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Pharmacognosy Magazine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yun, Debo</au><au>Yang, Yujiao</au><au>Shang, Bin</au><au>Dong, Heng</au><au>Luo, Bo</au><au>Alahmadi, Tahani</au><au>Luo, Qing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach</atitle><jtitle>Pharmacognosy Magazine</jtitle><date>2021-04-01</date><risdate>2021</risdate><volume>17</volume><issue>74</issue><spage>268</spage><epage>274</epage><pages>268-274</pages><issn>0973-1296</issn><eissn>0976-4062</eissn><abstract>Background: Ischemia/reperfusion (I/R)-induced stroke is a long-lasting disability. Numerous reports have demonstrated that inflammation is the major cause of ischemic cerebral injury. Therefore, it is important to develop an effective anti-inflammatory agent for the attenuation of I/R-induced brain injury. Objective: In this study, we examined the therapeutic role of kirenol against I/R-induced neuronal damage by inhibiting inflammation in Sprague-Dawley (SD) rats. Materials and Methods: I/R was induced in SD rats and subsequently were administered with 10 and 20 mg/kg of kirenol. Then, we assessed the neurological score, brain water content, and infarct size. The level of antioxidant enzymes, such as superoxide dismutase, catalase, glutathione, and acetylcholinesterase, as well as the levels of malondialdehyde, was measured by using standard methods. The level of tumor necrosis factor (TNF)-α; interleukin (IL)-1 β, IL-4, IL-6, and IL-10; and vascular endothelial growth factor was measured using standard kits. The targeted messenger RNA expression (NLRP3, NLRP4, TLR-4, TNF-α, caspase-1, ASC, and IL-1β) was quantified by polymerase chain reaction technique. Histopathological analysis of the brain tissue was performed. Results: According to our results, kirenol decreased the neurological deficit score, ameliorated the motor function, suppressed oxidative stress, reduced inflammation, and mediated the inhibition of TLR4/NLRP3-mediated inflammatory pathway. Conclusion: In conclusion, these findings demonstrate the protective effects of kirenol against I/R-induced cerebral injury. The mechanism of action is associated with the inhibition of inflammation through halting the TLR4/NLRP3 signaling pathway. In summary, kirenol is a potentially new compound which can be used to improve therapeutic strategies for stroke treatments.</abstract><cop>London</cop><pub>Wolters Kluwer India Pvt. Ltd</pub><doi>10.4103/pm.pm_261_20</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1296
ispartof Pharmacognosy Magazine, 2021-04, Vol.17 (74), p.268-274
issn 0973-1296
0976-4062
language eng
recordid cdi_proquest_journals_2553415866
source Publicly Available Content Database; Alma/SFX Local Collection
subjects Brain
Inflammation
Injuries
Neurons
Tumor necrosis factor-TNF
title Attenuation of kirenol inflammationinduced by ischemic/reperfusion cerebral infarction stroke via TLR4/ NLRP3 signaling pathway: An in vivo approach
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T21%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Attenuation%20of%20kirenol%20inflammationinduced%20by%20ischemic/reperfusion%20cerebral%20infarction%20stroke%20via%20TLR4/%20NLRP3%20signaling%20pathway:%20An%20in%20vivo%20approach&rft.jtitle=Pharmacognosy%20Magazine&rft.au=Yun,%20Debo&rft.date=2021-04-01&rft.volume=17&rft.issue=74&rft.spage=268&rft.epage=274&rft.pages=268-274&rft.issn=0973-1296&rft.eissn=0976-4062&rft_id=info:doi/10.4103/pm.pm_261_20&rft_dat=%3Cgale_proqu%3EA669072185%3C/gale_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c272t-725d27ea6a83a87418e0745d652fbecdce6c7318d4018d14b462caa85b698dbf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2553415866&rft_id=info:pmid/&rft_galeid=A669072185&rfr_iscdi=true